Market
Primary legal basis for federal court ruling on state bans of gender-affirming care by end of 2025?
2
Resolution / Starting Odds
Constitutional rights • 25%
State rights • 25%
Public health concerns • 25%
Other • 25%
Federal court rulings and legal documentation
Story
JAMA Pediatrics Study: Less Than 0.1% of U.S. Adolescents Received Gender-Affirming Medications Over Five Years
Jan 6, 2025, 08:00 PM
A recent study published in JAMA Pediatrics by Landon Hughes, a Harvard University public health researcher, has found that fewer than 1 in 1,000 U.S. adolescents with private insurance received gender-affirming medications, such as puberty blockers or hormones, over a five-year period from 2018 to 2022. The research, analyzing insurance claims data of over 5 million patients aged 8 to 17, indicates that less than 0.1% of these youth received such treatments. Specifically, 926 adolescents received puberty blockers, and 1,927 received hormones. The study highlights that no patients under the age of 12 were prescribed hormones, suggesting a cautious approach by healthcare providers. This data comes amid ongoing debates and legal challenges in the U.S. regarding healthcare for transgender youth, with at least 26 states having enacted laws restricting or banning these treatments for minors.
View original story
Similar markets
Partial ruling, modifying the ban • 25%
Strikes down the ban • 25%
Upholds the ban • 25%
Dismisses the case • 25%
Dismiss the case • 25%
Uphold the ban • 25%
Strike down the ban • 25%
Partial modification • 25%
Increase in similar bans • 25%
No change in similar bans • 25%
Mixed changes • 25%
Decrease in similar bans • 25%
Yes • 50%
No • 50%
Ban struck down • 25%
Case remanded to lower court • 25%
Other outcome • 25%
Ban upheld • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Ban struck down • 25%
Ban upheld • 25%
Other outcome • 25%
Case dismissed • 25%
No • 50%
Yes • 50%
